United States Antimony (UAMY) has significantly lowered its sales guidance for fiscal year 2026, reducing the outlook from $125 million to a range of $60 million to $75 million. This revised guidance falls substantially below the current analyst estimate of $114.038 million, indicating a material negative shift in the company's projected financial performance.
United States Antimony (UAMY) has issued a substantial downward revision to its FY2026 sales guidance, cutting it by approximately 40-50% from $125 million to $60-$75 million. This is a significant negative development as it indicates a much weaker future revenue stream than previously anticipated by both the company and analysts. The immediate impact will likely be a negative reaction in UAMY's stock price, as the market digests this reduced outlook. For traders, this presents a short-term bearish opportunity, as the stock is likely to trade down on this news. Long-term implications depend on the underlying reasons for the guidance cut, which are not disclosed in this filing, but it signals potential operational challenges or a weakening market for antimony.